Display options
Cite
Ling CS, Balp MM, Bjoerk B, et al. Pricing and Reimbursement Environment For A Biologic Obtaining A Licence In A Second Indication in Key European Countries. Value Health. 2014;17(7):A429doi: 10.1016/j.jval.2014.08.1084.
Ling, C. S., Balp, M. M., Bjoerk, B., Quijano, M., & Heyes, A. E. (2014). Pricing and Reimbursement Environment For A Biologic Obtaining A Licence In A Second Indication in Key European Countries. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 17(7), A429. https://doi.org/10.1016/j.jval.2014.08.1084
Ling, C S, et al. "Pricing and Reimbursement Environment For A Biologic Obtaining A Licence In A Second Indication in Key European Countries." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 17,7 (2014): A429. doi: https://doi.org/10.1016/j.jval.2014.08.1084
Ling CS, Balp MM, Bjoerk B, Quijano M, Heyes AE. Pricing and Reimbursement Environment For A Biologic Obtaining A Licence In A Second Indication in Key European Countries. Value Health. 2014 Nov;17(7):A429. doi: 10.1016/j.jval.2014.08.1084. Epub 2014 Oct 26. PMID: 27201116.
Copy Download .nbib Format: NLM
Share it on

Value Health. 2014 Nov;17(7):A429. doi: 10.1016/j.jval.2014.08.1084. Epub 2014 Oct 26.

Pricing and Reimbursement Environment For A Biologic Obtaining A Licence In A Second Indication in Key European Countries.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

C S Ling, M M Balp, B Bjoerk, M Quijano, A E Heyes

Affiliations

  1. RTI Health Solutions, Manchester, UK.
  2. Novartis Pharma AG, Basel, Switzerland.

PMID: 27201116 DOI: 10.1016/j.jval.2014.08.1084

[No abstract available.]

Publication Types